Industry groups are calling for stronger competitiveness incentives as the EU prepares for implementation of the EU Biotech Act. Companies and stakeholders say support needs to go beyond incremental adjustments to restore Europe’s position across the drug lifecycle—from early academic work through clinical development and manufacturing to commercialization. The message is that regulatory framework alone will not be enough to attract and retain investment without policies that improve the economics of bringing medicines to market in Europe. Backers are seeking a system that reduces friction and funding gaps throughout the full development path. For biotech executives, the proposal is a near-term policy test: whether the EU can translate legislative ambition into incentives that influence site selection, trial execution, and industrial scaling.